Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 11, 2011 Brian Stoffel	Can You Predict the Future? A check back on ten different stocks offers perspective.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool September 21, 2010 Eric Bleeker	5 Stocks We're Buying As part of our "11 O'Clock Stock" series, we're buying these five stocks.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool September 8, 2010 Ron Gross	Today's Buy Opportunity: Domino's Pizza Do you love pizza? Well, then Domino's Pizza may be an investment that's as tasty as a fresh made-to-order slice of pie.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool August 12, 2011 Matt Koppenheffer	3 Stocks I Bought During the Panic With Mr. Market lowering prices on nearly everything, I did some shopping.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool June 9, 2010	Is IBM a Buy? While other tech companies -- such as Apple -- take a lot of heat for hoarding cash, IBM leverages its balance sheet better than any other tech company.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool September 8, 2005 Stephen D. Simpson	Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either.
The Motley Fool April 5, 2011 Brian Orelli	Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva.
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.
The Motley Fool September 10, 2010 Charly Travers	Today's Buy Opportunity: Take-Two Interactive The gaming software stock has been beaten down like a Liberty City thug. That's good news for investors.
The Motley Fool January 15, 2008 Brian Orelli	Fewer Generics in Fido's Future TEVA considers selling its small animal-health business.
The Motley Fool September 7, 2010 Eric Bleeker	Today's Buy Opportunity: IBM Today's Motley Fool 11 O'Clock Stock pick gets the job done.
The Motley Fool October 5, 2011 Dan Caplinger	Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future.
The Motley Fool May 17, 2006 Rick Aristotle Munarriz	Cheat Codes for April Video games bounced back last month, but it's only a blip. That may be problematic if your entire portfolio consists of shares of THQ, Take-Two Interactive, and Atari, but it's not as if you didn't see this coming.
The Motley Fool June 9, 2010 Anders Bylund	Is Take-Two Interactive a Sell? Take-Two Interactive Software just beat every reasonable expectation for the second quarter. But halfway decent numbers don't matter much when management can't focus on what's important.
The Motley Fool May 5, 2009 Brian Orelli	Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool November 9, 2010 Eric Bleeker	Portfolio Checkup: 3 Stocks Soaring, 3 Stocks Sagging Checking in on the "11 O'Clock Stock" portfolio from July, in which Motley Fool analysts picked 50 stocks over 50 weekdays.
The Motley Fool December 14, 2009 Rich Smith	This Just In: Upgrades and Downgrades Piper Jaffray plays a wrong note on Teva.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
InternetNews March 30, 2006 Clint Boulton	The Deal: $20K to Leave Exchange For Lotus IBM offers money to resellers who can get customers to migrate from Exchange to Lotus Notes and Domino.
The Motley Fool October 17, 2006 Anders Bylund	Foolish Forecast: A Trim IBM The information giant is set to report earnings for third-quarter 2006. Investors, here's what to expect and why.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool May 10, 2006 Stephen D. Simpson	Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note.
The Motley Fool May 11, 2011 Jared Cummans	Wednesday's ETF to Watch: iShares MSCI Israel Fund Teva Pharmaceuticals releases earnings today.
The Motley Fool September 25, 2008 Brian Orelli	Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play?
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool June 6, 2005 Stephen D. Simpson	"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position.
InternetNews October 16, 2007 Larry Barrett	IBM Nips 3Q Estimates But Hardware Sales Slip Some of IBM's server and mainframe units suffered through a lackluster quarter but the company said it's still on track to meet its lofty earnings targets for this year and through 2010.
The Motley Fool October 13, 2006 David Meier	Retail in Review See what the past week brought to the retail sector. Monday: It was a slow day... Tuesday: Tower records is sold to a liquidator... Wednesday: Cheesecake Factory issued a sales update... etc.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool June 10, 2011 Matt Koppenheffer	Could Teva Pharmaceutical Score You 100% Returns? Is it high time to add Teva's stock to your portfolio?
The Motley Fool February 25, 2008 Brian Orelli	Look Across the Pond for Biosimilars Teva, ratiopharm, and CT Arzneimittel all get positive recommendations for their new biosimilars, as approvals for generic equivalents to biotech drugs are heating up in Europe.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.
The Motley Fool February 27, 2009 Brian Orelli	Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas.
The Motley Fool January 23, 2008 Brian Orelli	Teva Buys In to Biologics Teva Pharmaceutical announces that it was acquiring privately held CoGenesys, for $400 million in cash.
The Motley Fool July 18, 2011 Brian Orelli	A $3.6 Billion Franchise at Stake Amgen and Teva settle their patent dispute, and Amgen investors have a little better idea of when the company's $3.6 billion Neupogen and Neulasta franchise might come under attack in the United States.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.